TrialAnnals of oncology : official journal of the European Society for Medical Oncology2020

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.

E L Mayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.